forest laboratories

Citigroup has downgraded Forest Laboratories (NYSE: FRX) from Buy to Hold and has lowered the price target from $39 to $35.

JP Morgan has published a research report on Forest Laboratories (NYSE: FRX) and has upgraded the company from Underweight to Neutral. In the report, JP Morgan writes "We are upgrading FRX shares to Neutral from Underweight and raising our price target to $34. While we continue to have concerns...

JP Morgan has upgraded Forest Laboratories (NYSE: FRX) from Underweight to Neutral and has raised the price target from 432 to $34.

Piper Jaffray has raised the price target on Forest Laboratories (NYSE: FRX) from $29 to $31 and maintains its Underweight rating.

Citigroup has published a research report on Forest Laboratories (NYSE: FRX) and has raised estimates and the price target on the company in response to FY2Q11 post view. In the report, Citigroup writes “We raised our price target from $33 both based on the increase in our CY2011E EPS from $4.11...

Forest Laboratories, Inc. (NYSE: FRX) was voted unanimously by the FDA Anti-Infective Drugs Advisory Panel Committee in favor of approval of FRX's ceftaroline or both community acquired bacterial pneumonia (CABP) and complicated skin and skin structure infections (cSSSI), Oppenheimer reports. The...